MedTrace Logo

Biomarkers of Renal Dysfunction in Neuroblastoma Survivors

NCT03947346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2025-07-17

No results posted yet for this study

Summary

The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.

Conditions

  • Neuroblastoma Survivors

Interventions

OTHER

Urine sample

The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.

Sponsors & Collaborators

Principal Investigators

  • Danielle Friedman, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-09
Primary Completion
2025-07-15
Completion
2025-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03947346 on ClinicalTrials.gov